CERE - Cerevel reports positive data in phase 1 trial of darigabat for anxiety

Cerevel Therapeutics (NASDAQ:CERE) reported results from a phase 1 trial of darigabat in healthy volunteers for acute anxiety. The company said the 7.5 mg twice-daily and the 25 mg twice-daily doses of darigabat showed clinically meaningful and statistically significant anxiolytic activity compared with placebo in the proof-of-principle trial. The positive control alprazolam 1 mg twice-daily exhibited placebo-adjusted anxiolytic activity in line with expectations for this trial design. Following eight days of treatment, the darigabat 7.5 mg and 25 mg twice-daily doses showed a 3.9 point and 4.5 point placebo-adjusted improvement, respectively, on the main goal of the Panic Symptoms List (PSL-IV) total score. Alprazolam showed a 1.6 point placebo-adjusted improvement on the PSL-IV total score. The company added that the the results were further supported by the secondary goals of change in the Fear Visual Analog Scale, which demonstrated a 12.8 point, 7.8 point, and 0.9 point placebo-adjusted improvement for the

For further details see:

Cerevel reports positive data in phase 1 trial of darigabat for anxiety